These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19827992)

  • 1. Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy.
    Nelson SP; Kothari S; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
    J Med Econ; 2009; 12(4):348-55. PubMed ID: 19827992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.
    Kothari S; Nelson SP; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
    Curr Med Res Opin; 2009 Nov; 25(11):2703-9. PubMed ID: 19775195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
    Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A;
    Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study.
    Alexandropoulou K; van Vlymen J; Reid F; Poullis A; Kang JY
    Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):15-21. PubMed ID: 23022985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study.
    Kim KM; Cho YK; Bae SJ; Kim DS; Shim KN; Kim JH; Jung SW; Kim N
    J Gastroenterol Hepatol; 2012 Apr; 27(4):741-5. PubMed ID: 21916988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical cost, incidence rate, and treatment status of gastroesophageal reflux disease in Japan: analysis of claims data.
    Miwa H; Takeshima T; Iwasaki K; Hiroi S
    J Med Econ; 2016 Nov; 19(11):1049-1055. PubMed ID: 27207316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study.
    El-Serag HB; Fitzgerald S; Richardson P
    Am J Gastroenterol; 2009 Sep; 104(9):2161-7. PubMed ID: 19568229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.
    Gosselin A; Luo R; Lohoues H; Toy E; Lewis B; Crawley J; Duh MS
    Value Health; 2009; 12(1):34-9. PubMed ID: 19895371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J; Dodd S; Durkin M; Sloan S
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns in paediatric patients with a new diagnosis of gastroesophageal reflux disease.
    Ruigómez A; Hungin AP; Lundborg P; Johansson S; Wallander MA; García Rodríguez LA
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):232-7. PubMed ID: 21258240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
    Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
    Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
    Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
    Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked increase in proton pump inhibitors use in Australia.
    Hollingworth S; Duncan EL; Martin JH
    Pharmacoepidemiol Drug Saf; 2010 Oct; 19(10):1019-24. PubMed ID: 20623646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitor utilization patterns in infants.
    Barron JJ; Tan H; Spalding J; Bakst AW; Singer J
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):421-7. PubMed ID: 18030207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a refractory gastro-oesophageal reflux score using an administrative claims database.
    Gerson LB; Bonafede M; Princic N; Gregory C; Farr A; Balu S
    Aliment Pharmacol Ther; 2011 Sep; 34(5):555-67. PubMed ID: 21714794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in prescription patterns of acid-suppressant medications by Belgian pediatricians: analysis of the national database, [1997-2009].
    De Bruyne P; Christiaens T; Vander Stichele R; Van Winckel M
    J Pediatr Gastroenterol Nutr; 2014 Feb; 58(2):220-5. PubMed ID: 24464148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Study of Gastroesophageal Reflux, Use of Proton Pump Inhibitors and H2-Receptor Antagonists, and Risk of Hearing Loss.
    Lin BM; Curhan SG; Wang M; Jacobson BC; Eavey R; Stankovic KM; Curhan GC
    Ear Hear; 2017; 38(1):21-27. PubMed ID: 27556519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
    Landi SN; Sandler RS; Pate V; Lund JL
    Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.
    Cohen S; Bueno de Mesquita M; Mimouni FB
    Br J Clin Pharmacol; 2015 Aug; 80(2):200-8. PubMed ID: 25752807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
    Higginbotham TW
    Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.